Brown & Brown is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The business quality is solid and the latest quarter showed strong revenue and net income growth, but the stock’s technical setup is still weak, hedge funds are selling, and recent analyst target cuts outweigh the single upgrade. I would not buy aggressively here; hold and wait for a clearer trend improvement.
BRO is in a short-term downtrend. MACD histogram is negative at -0.864, the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, and RSI_6 at 29.345 suggests the stock is weak rather than confirming a strong reversal. Price at 58.06 is below the pivot of 61.331 and only slightly above support at 57.267, so the chart does not show a clean long-term entry yet.

In Q1 2026, Brown & Brown posted revenue of $1.901 billion, up 35.4% YoY, and net income of $421 million, up 28.75% YoY. That is a strong top-line and bottom-line growth quarter. However, EPS declined to $1.06, down 7.83% YoY, so earnings per share quality was not as strong as headline profit growth suggests. Overall, the latest quarter season was strong on growth, but not perfectly clean on per-share earnings.
Wall Street is mixed but leaning constructive. Citi upgraded the stock to Buy, while Truist still has Buy and Mizuho has Outperform. However, several firms lowered targets recently, with Raymond James cutting to $65, Morgan Stanley to $65, RBC to $72, Keefe Bruyette to $72, BofA to $85, and JPMorgan to $85. The pros argue valuation is attractive and organic growth and free cash flow remain solid; the cons focus on slower near-term growth and target reductions. Net view: positive long-term thesis, but near-term expectations have been trimmed.